NCT07148310Recruiting
Hepatocellular Carcinoma Identification Using Delta-HLD
Proof-of-Concept Case-Control Study for Hepatocellular Carcinoma Identification Using Delta-HLD Technology (HIDE)
Source: ClinicalTrials.gov · Last updated 9 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 22 Aug 2025
- Start date
- 18 May 2023
- Primary completion date
- 12 Aug 2026
- Lead sponsor
- Epiliquid Holding, Inc
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07148310
What you commit to
- Study type: Observational
- Planned participants: 200
- From 18 May 2023 to the primary completion date, 12 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior liver transplantation
- Recent chemotherapy or antiviral treatment (\<3 months)
Other illness
- Other active cancers
- Known hereditary cancer syndromes
Who the study is looking for
- Histologically confirmed HCC (cases) or clinically confirmed liver cirrhosis without HCC (controls)
- Willing and able to provide informed consent
- Available paired plasma and liver tissue sample
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Epiliquid Coordinator of this site? Confirm its status | Mendoza | Argentina | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.